David Ricks, the CEO of Eli Lilly, is doubling down on the world’s obsession with the perfect waistline. The pharmaceutical giant announced an additional $4.5 billion investment in its Indiana manufacturing sites, bringing the total commitment to a staggering $9 billion.

The money is being poured into the Lilly Lebanon Advanced Therapies site to keep up with the “intense global appetite” for Zepbound and Mounjaro, according to the Chronicle-Journal. Sales for Mounjaro in Japan alone surged by 280% last year, proving that vanity is the only truly universal currency.

While the masses wait for Medicare’s $245 price cap to kick in this July, Lilly is building the largest API production site in U.S. history. Ricks said in a statement that the expansion will support everything from research to large-scale commercial activities for next-gen assets.

This column finds the physical scale of the investment a beautiful testament to our priorities. We are building cathedrals of chemistry to ensure that no one ever has to look at a carbohydrate again.

It is the dawn of the Metabolic Divide. On one side, the elite secede into a world of bespoke, genetic medicine and $150,000-a-year private chefs; on the other, the government subsidizes the injectables to keep the workforce lean and compliant.

In Lebanon, Indiana, the dirt is being turned for a future where hunger is a choice and a slender profile is an industrial product. We aren't just buying drugs; we are buying a new biological social standing.